|
Prana Biotechnology Limited (ADR) (PRAN): Phase II Results Approaching For …
Seeking Alpha The main focus to date in the evolution in treatment for dementia has been monoclonal antibodies to the amyloid plaques found in Alzheimer's dementia. This approach has been littered with failures namely Bapineuzumab a product of JNJ and PFE which … |
